American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer Export

@article{citeulike:2294120, abstract = {PurposeTo update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer. MethodsFor the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and analysis of data published since 1999. Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed. The Update Committee's literature review focused attention on available systematic reviews and meta-analyses of published tumor marker studies. In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations. Recommendations and ConclusionsThirteen categories of breast tumor markers were considered, six of which were new for the guideline. The following categories showed evidence of clinical utility and were recommended for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multiparameter gene expression assays. Not all applications for these markers were supported, however. The following categories demonstrated insufficient evidence to support routine use in clinical practice: DNA/ploidy by flow cytometry, p53, cathepsin D, cyclin E, proteomics, certain multiparameter assays, detection of bone marrow micrometastases, and circulating tumor cells. 10.1200/JCO.2007.14.2364}, author = {Harris, Lyndsay and Fritsche, Herbert and Mennel, Robert and Norton, Larry and Ravdin, Peter and Taube, Sheila and Somerfield, Mark R. and Hayes, Daniel F. and Bast, Robert C.}, citeulike-article-id = {2294120}, citeulike-linkout-0 = {http://dx.doi.org/10.1200/JCO.2007.14.2364}, citeulike-linkout-1 = {http://jco.ascopubs.org/cgi/content/abstract/25/33/5287}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/17954709}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=17954709}, comment = {Recommended tumour markers: * CA 15-3, * CA 27.29, * Carcinoembryonic Antigen, * estrogen receptor, * progesterone receptor, * human epidermal growth factor receptor 2, * urokinase plasminogen activator, * plasminogen activator inhibitor 1, * certain multiparameter gene expression assays}, day = {20}, doi = {10.1200/JCO.2007.14.2364}, journal = {J Clin Oncol}, keywords = {2007, asco, breast, cancer, markers, recommendations, tumour}, month = {November}, number = {33}, pages = {5287--5312}, posted-at = {2008-12-07 04:08:00}, priority = {2}, title = {American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer}, url = {http://dx.doi.org/10.1200/JCO.2007.14.2364}, volume = {25}, year = {2007} }

TY - JOUR ID - citeulike:2294120 L3 - citeulike-article-id:2294120 N2 - PurposeTo update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer. MethodsFor the 2007 update, an Update Committee composed of members from the full Panel was formed to complete the review and analysis of data published since 1999. Computerized literature searches of MEDLINE and the Cochrane Collaboration Library were performed. The Update Committee's literature review focused attention on available systematic reviews and meta-analyses of published tumor marker studies. In general, significant health outcomes (overall survival, disease-free survival, quality of life, lesser toxicity, and cost-effectiveness) were used for making recommendations. Recommendations and ConclusionsThirteen categories of breast tumor markers were considered, six of which were new for the guideline. The following categories showed evidence of clinical utility and were recommended for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, urokinase plasminogen activator, plasminogen activator inhibitor 1, and certain multiparameter gene expression assays. Not all applications for these markers were supported, however. The following categories demonstrated insufficient evidence to support routine use in clinical practice: DNA/ploidy by flow cytometry, p53, cathepsin D, cyclin E, proteomics, certain multiparameter assays, detection of bone marrow micrometastases, and circulating tumor cells. 10.1200/JCO.2007.14.2364 IS - 33 JF - J Clin Oncol EP - 5312 TI - American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer VL - 25 SP - 5287 KW - 2007 KW - asco KW - breast KW - cancer KW - markers KW - recommendations KW - tumour N1 - Recommended tumour markers: * CA 15-3, * CA 27.29, * Carcinoembryonic Antigen, * estrogen receptor, * progesterone receptor, * human epidermal growth factor receptor 2, * urokinase plasminogen activator, * plasminogen activator inhibitor 1, * certain multiparameter gene expression assays AU - Harris, Lyndsay AU - Fritsche, Herbert AU - Mennel, Robert AU - Norton, Larry AU - Ravdin, Peter AU - Taube, Sheila AU - Somerfield, Mark AU - Hayes, Daniel AU - Bast, Robert PY - 2007/11/20/ UR - http://dx.doi.org/10.1200/JCO.2007.14.2364 ER -